AUTHORS
Jessica Liegel, MD, Lina Bisharat, MSc2, Giulia Cheloni, PhD3, Malgorzata McMasters, MD4, Kevin Barnum, MD, PhD5, Bimalangshu Dey, MD6, Peter Tonzi, MD, PhD7, Hazal Toros8, Zoe Sokol9, Sam Herzlinger10, Abigael Morin11, Jonah Lee12, John Clohessy13, Jacalyn Rosenblatt, MD14, David E. Avigan, MD15
AFFILIATIONS
1 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
2 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
3 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
4 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
5 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
6 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
7 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
8 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
9 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
10 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
11 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
12 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
13 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
14 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
15 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
ABSTRACT
Background:
Although decitabine/venetoclax (Dec/Ven) produces high response rates in acute myeloid leukemia (AML), relapse remains common, particularly in patients with persistent measurable residual disease. Adoptive transfer of autologous T cells primed ex vivo with patient-specific dendritic cell (DC)/AML fusion vaccine may augment leukemia-directed immunity. We previously reported T cell activation, cytotoxicty and enhanced survival in a murine model. We subsequently developed a translational strategy using Dec/Ven both as AML therapy and a conditioning platform for DC/AML-primed T cells.
Methods:
To establish the rationale for clinical translation with decitabine/venetoclax backbone, we tested persistence of transferred T cells in a murine model. CD45.1 C57BL/6 mice received Dec/Ven for 7 days or no conditioning (n=5/group), followed by adoptive transfer of expanded CD45.2+ OT1 CD8+ T cells and ovalbumin peptide stimulation. Donor-cell persistence was assessed in blood, marrow, and spleen. To evaluate feasibility of DC/AML Primed T cells, we conducted clinical manufacturing runs. DC/AML Primed T cells are generated by ex-vivo dendritic cell vaccine priming of autologous PBMCs followed by selection for CD4/CD8 and expansion on CliniMACS Prodigy with human IL2, IL7 and IL15. We evaluated planned release criteria including yield and phenotyping by flow cytometric analysis.
Results:
In the murine model, Dec/Ven increased circulating transferred donor CD45.2+CD3+ T cells (mean, 1.16 vs 0.26 K/μL; P≤0.01), with enrichment in marrow (6.4% vs 0.69% of CD45+ cells; P=0.0653) and spleen (5.6% vs 1.4%; P=0.0653). In manufacturing runs with primary leukemia cells and autologous dendritic cells, DC/AML-primed T-cell products were successfully manufactured for 3 separate patients. Approximately 30-40×106 cells at the start of expansion yielded 1.8-5.7×10? cells after 7-10 days, exceeding projected requirements for the planned dose range of 1×106 to 1×107 cells/kg. Products contained both CD4+ helper and CD8+ effector populations. Mean CD25+CD69+ and 4-1BB+ populations increased from approximately 2% and 2% at leukapheresis to 22% and 14% after vaccine priming and magnetic bead selection, followed by contraction of these transient activation markers during expansion. Final products were highly T-cell enriched (mean 98% CD45+CD3+) and memory enriched, comprising approximately 19% central memory and 75% effector memory T cells, with minimal terminally differentiated effector memory RA (TEMRA) cells.
Conclusions:
These preclinical and initial patient-specific manufacturing data define a direct path from platform development to clinical trial protocol. Persistence of adoptively transferred T cells is enhanced after infusion during nadir of Dec/Ven. This supports use of Dec/Ven as a conditioning platform prior to cell infusion. The robust expansion, high T-cell purity, and memory-favorable phenotype achieved in the first three clinical products provide manufacturing feasibility and delivery at dose levels up to 1×107 cells/kg. Together, these findings provide the biologic and operational rationale for this first-in-human strategy integrating serial DC/AML-primed T-cell infusions and vaccine boosts in combination with standard Dec/Ven therapy in AML.
DISCLOSURES
Jessica Liegel, MD: Janssen - Research Funding; Sanofi - Research Funding